CD30

CD30 Molekülinformation

Englischer Name	Tumor necrosis factor receptor superfamily member 8	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	23	Target-Alias	CD30，CD30L receptor，TNFRSF8，Lymphocyte activation antigen CD30，TNF Receptor Superfamily Member 8，D1S166E，Tumor Necrosis Factor Receptor Superfamily， Member 8，Cytokine Receptor CD30，CD30 Antigen，Ki-1，Ki-1 Antigen，Tumor Necrosis Factor Receptor Superfamily Member 8
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Tumor necrosis factor receptor superfamily member 8
Target-Alias	CD30，CD30L receptor，TNFRSF8，Lymphocyte activation antigen CD30，TNF Receptor Superfamily Member 8，D1S166E，Tumor Necrosis Factor Receptor Superfamily， Member 8，Cytokine Receptor CD30，CD30 Antigen，Ki-1，Ki-1 Antigen，Tumor Necrosis Factor Receptor Superfamily Member 8
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	23
Höchste Forschungs- und Entwicklungsphase	Approved

CD30 Produktliste

Attribut
Protein (8)
Produktbibliothek
Online (8)
Spezies
Human (8)
Etikett
Fc Tag (2)His Tag & Avi Tag (1)Llama IgG Fc Tag (1)His Tag (3)Fc Tag & Avi Tag (1)
Marker
Unconjugated (3)Biotin-labeled (2)FITC Labeled (2)PE Labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT CD0-H52H5	Human	HEK293	Human CD30 / TNFRSF8 Protein, His Tag, low endotoxin	In den Warenkorb legen
HOT CD0-H82E6	Human	HEK293	Biotinylated Human CD30 / TNFRSF8 Protein, Avitag™,His Tag (MALS verified)	In den Warenkorb legen
HOT CD0-HP2E3	Human	HEK293	PE-Labeled Human CD30 / TNFRSF8 Protein, His Tag (Site-specific conjugation)	In den Warenkorb legen
CD0-H5250	Human	HEK293	Human CD30 / TNFRSF8 Protein, Fc Tag (MALS verified)	In den Warenkorb legen
CD0-H82F4	Human	HEK293	Biotinylated Human CD30 / TNFRSF8 Protein, Fc,Avitag™ (MALS verified)	In den Warenkorb legen
CD0-HF250	Human	HEK293	FITC-Labeled Human CD30 / TNFRSF8 Protein, Fc Tag	In den Warenkorb legen
CD0-HF2H4	Human	HEK293	FITC-Labeled Human CD30 / TNFRSF8 Protein, His Tag	In den Warenkorb legen
TN8-H5250	Human	HEK293	Human CD30 / TNFRSF8 Protein, Llama IgG2b Fc Tag, low endotoxin	In den Warenkorb legen

Gesamtmenge8

CD30 Molekülhintergrund

Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.

CD30 Molekülalias

TNFRSF8,CD30,D1S166E,Ki-1

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Acimtamig	AFM-13	Phase 2 Clinical	The University Of Texas MD Anderson Cancer Center	Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mycosis Fungoides	Details
ATLCAR.CD30 cells (UNC Lineberger Comprehensive Cancer Center)		Phase 2 Clinical	Unc Lineberger Comprehensive Cancer Center	Lymphoma, T-Cell, Peripheral; Lymphatic Diseases; Immunoproliferative Disorders; Neoplasms; Hodgkin Disease; Immune System Diseases; Lymphoproliferative Disorders; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms, Germ Cell and Embryonal	Details
Autologous CD30+ CAR T Cells therapy(New York Medical College)		Phase 2 Clinical	New York Medical College, University Of North Carolina At Chapel Hill	Hodgkin Disease	Details
Itezocabtagene autoleucel	TT-11; TT11	Phase 2 Clinical	Tessa Therapeutics Ltd	Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic	Details
BRD-01	BRD-01	Phase 2 Clinical	Wuhan BioRaid Biotechnology Co Ltd	Hematologic Neoplasms; Hodgkin Disease	Details
CD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit)		Phase 2 Clinical	The Medical College Of Wisconsin Nonprofit	Lymphoma, B-Cell; Leukemia; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma; Lymphoma, T-Cell, Cutaneous	Details
HSP-CAR-30	HSP-CAR-30	Phase 2 Clinical	Fundació Institut De Recerca De L	Hodgkin Disease; Lymphoma, T-Cell	Details
Anti-CD30 CAR T-cell therapy (General Hospital of the People's Liberation Army/Cellular Biomedicine)	CAR30-NKT; CBM-C30.1; CD30ScFv-CD8-CD137-CD3zeta	Phase 2 Clinical	Pla General Hospital	Hodgkin Disease	Details
Anti-CD30 chimeric antigen receptor T cell therapy (Immune cell)		Phase 1 Clinical	Immune Cell Inc	Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic	Details
CD30.CAR-EBVST cell therapy (Baylor College of Medicine)	TT-11X	Phase 1 Clinical	Baylor College Of Medicine, Tessa Therapeutics Ltd	Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell	Details
EBV-specific-CAR.CD30	EBV-specific-CAR.CD30; CAR.CD30 EBV-specific-CTLs	Phase 1 Clinical	Baylor College Of Medicine, Texas Children'S Hospital, Methodist Hospital System	Hodgkin Disease; Lymphoma, Non-Hodgkin	Details
Anti-CD30 CAR T-cell therapy (Wuhan Bio-Raid)		Phase 1 Clinical	Wuhan BioRaid Biotechnology Co Ltd	Lymphoma, T-Cell, Peripheral; Hematologic Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Angioimmunoblastic T-cell Lymphoma	Details
Recombinant chimeric anti-CD30 monoclonal antibody-MCC-DM1	F0002-ADC; B-006(SCP)	Phase 1 Clinical	Shanghai Crosslink Pharmaceutical R & D Co Ltd, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd	Hematologic Neoplasms; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic	Details
CD30.CAR	H-27721; CD30.CAR	Phase 1 Clinical	Baylor College Of Medicine	Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic	Details
Anti-CD20/CD30-CAR-T Cell therapy(Shanghai Tongji Hospital)		Phase 1 Clinical	Shanghai Tongji Hospital	Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma	Details
CD30-Targeted LCAR-HL30 Cells therapy(Legend Biotechnology)		Phase 1 Clinical	Nanjing Legend Biotechnology Co Ltd	Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic	Details
SGN-35C	SGN-35C	Phase 1 Clinical	Seagen Inc	Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma; Lymphoma, Large-Cell, Anaplastic	Details
SGN-35T	SGN-35T; SGN-CD30C; PF-08046045	Phase 1 Clinical	Seagen Inc	Solid tumours; Lymphoma, T-Cell, Peripheral; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous	Details
Anti-CD30 CAR T-cell therapy		Phase 1 Clinical	Minghui (Nanjing) Gene Biotechnology Co Ltd	Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic	Details
Anti-CD30 CAR-T cell therapy (National Cancer Institute)	Hu30-CD28z	Phase 1 Clinical	National Cancer Institute	Lymphoma, T-Cell, Peripheral; Enteropathy-Associated T-Cell Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma	Details
PRA-052	PRA-052	Phase 1 Clinical	Prometheus Biosciences Inc	Colitis, Ulcerative	Details
SGN-CD30C	SGN-CD30C	Phase 1 Clinical	Seattle Genetics Inc	Lymphoma	Details
Anti-CD30 chimeric antigen receptor T cell therapy (Yake Biotechnology)		Clinical	Shanghai YaKe Biotechnology Co Ltd	Hodgkin Disease	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Brentuximab vedotin	SGN-35; cAC10-vcMMAE; SGN-30; cAC10-Val-Cit-MMAE; cAC-10; SGD-1010	Approved	Seagen Inc	Adcetris, 安适利	United States	Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic	Seagen Inc	2011-08-19	Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Sezary Syndrome; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous; Scleroderma, Diffuse; Leukemia, Mast-Cell; Lymphoma, T-Cell; Hidradenitis Suppurativa; Lymphoma; Neoplasms, Germ Cell and Embryonal; Mycosis Fungoides; Lymphomatoid Papulosis; Sarcoma, Kaposi; Graft vs Host Disease; Solid tumours; Lymphoma, B-Cell; Hematologic Diseases; HIV Infections; Hematologic Neoplasms; Carcinoma; Anemia, Refractory, with Excess of Blasts; Hodgkin Disease; Lymphoma, T-Cell, Peripheral; Lymphoma, Large B-Cell, Diffuse; Scleroderma, Systemic; Enteropathy-Associated T-Cell Lymphoma; Myelodysplastic Syndromes; Neoplasms; Mastocytosis, Systemic; Mesothelioma	Details

Produktrezensionen

R***s2021-09-22
3Menschen mögen
FITC-Labeled Human CD30 / TNFRSF8 Protein, His Tag
Our research group work with CAR-T therapy for the treatment of hematological malignancies, and use the Fitc-Labeled Human CD30 protein for detection of CAR30 cells in patients by flow cytometry. Our results are fantastic, because the observe consistency and a reproducible experiments by flow cytometry. The logistic speed is very effective and allows us to work always up to date with our projects.
1***22020-01-10
0Menschen mögen
Human CD30 / TNFRSF8 Protein, Fc Tag (MALS verified)
There are many CD30 products, with various tags. What I chose was the hFc tag protein. I also purchased CD30L for Fortebio experiment. The result was pretty good.